Danish Communications Stock News

Coloplast has recently announced upcoming changes to its Executive Leadership Team, with long-serving leaders in People & Culture and Interventional Urology set to depart and successors, including incoming Interventional Urology head Kevin Hardage from Teleflex, lined up to ensure business continuity. These leadership shifts, particularly in the Interventional Urology division and the global People & Culture function, could influence how effectively Coloplast executes its reorganisation,...

Rockwool (CPSE:ROCK B) has quietly turned a corner in the past month, with the stock up about 8% even as its year to date performance and 1 year returns remain in the red. See our latest analysis for Rockwool. That recent 1 month share price return of just over 8% has only partially offset a weak year to date share price return and slightly negative 1 year total shareholder return, so the move looks more like early momentum than a full trend change. If Rockwool’s shift has you rethinking your...

AL Sydbank stock performance and recent backdrop AL Sydbank (CPSE:ALSYDB) has quietly delivered strong returns for patient shareholders, with the share price up about 46% year to date and roughly 67% over the past year, outpacing many Nordic peers. See our latest analysis for AL Sydbank. After a strong run, the recent 7 day share price return of negative 2.71 percent looks more like a breather than a reversal. Momentum is still supported by a robust 1 year total shareholder return of 67.01...

TORM (CPSE:TRMD A) has just shaken up its leadership by appointing veteran dealmaker Simon Mackenzie Smith as Chair of the Board, a move that could subtly reshape strategy, capital allocation, and investor expectations. See our latest analysis for TORM. The leadership change comes as TORM’s 30 day share price return of minus 14.42 percent and year to date share price return of minus 16.41 percent contrast with a resilient 1 year total shareholder return of 5.99 percent. This suggests short...

It's not a stretch to say that WindowMaster International A/S' ( CPH:WMA ) price-to-sales (or "P/S") ratio of 0.5x...

Key Insights Significant control over H. Lundbeck by private equity firms implies that the general public has more...

Per Aarsleff Holding A/S' ( CPH:PAAL B ) dividend will be increasing from last year's payment of the same period to...

Novo Nordisk has filed for FDA approval of its new combination obesity therapy CagriSema. European regulators have issued a positive opinion on a higher dose of Wegovy, supporting a potential label expansion. The company is advancing an oral semaglutide pill and has executed strategic acquisitions and leadership changes. CPSE:NOVO B is reshaping its obesity and metabolic franchise at a time of intense competitive pressure, particularly from Eli Lilly. The company is adding CagriSema and a...

In recent days, Vestas Wind Systems has announced a string of new turbine orders, including an 828 MW contract in Brazil with Casa dos Ventos alongside additional projects in Finland, Germany, Poland, Italy and Australia, many supported by long-term service agreements extending up to 25 years. This wave of geographically diverse wins underscores Vestas’ ability to pair equipment sales with multi-decade service contracts, potentially deepening recurring revenue visibility across multiple...

SP Group (CPH:SPG) has had a great run on the share market with its stock up by a significant 17% over the last month...

It is hard to get excited after looking at Dampskibsselskabet Norden's (CPH:DNORD) recent performance, when its stock...

Roblon A/S ( CPH:RBLN B ) shareholders would be excited to see that the share price has had a great month, posting a...

Short term slide and longer term context Novo Nordisk (CPSE:NOVO B) has quietly slipped over the past few months, with the stock down about 1 % this month and roughly 21 % over the past 3 months, inviting closer attention. See our latest analysis for Novo Nordisk. Zooming out, the recent pullback sits against a much tougher backdrop, with a steep year to date share price return decline and a similarly weak 1 year total shareholder return suggesting momentum has clearly cooled despite solid...

Genmab (CPSE:GMAB) just put epcoritamab back in the spotlight by unveiling fresh ASH 2025 data across multiple lymphoma trials that sharpen the drug’s profile and give investors more to consider. See our latest analysis for Genmab. Those ASH readouts land at a time when momentum in Genmab’s shares is clearly building, with a roughly 32% year to date share price return and a 36% one year total shareholder return, in contrast with still negative three year total shareholder returns. If...

Per Aarsleff Holding (CPSE:PAAL B) has posted another solid update for FY 2025, with third quarter revenue of DKK 5.8 billion and EPS of DKK 12.37, setting the tone for a year that is tracking steadily against last year’s performance. The company has seen quarterly revenue move between DKK 5.2 billion and DKK 5.8 billion over the last three quarters, while EPS has ranged from DKK 8.84 to DKK 12.37. This gives investors a clear view of how earnings are holding up as margins ease slightly from...

Danske Bank has completed its three-year corporate probation with the U.S. Department of Justice, closing all formal processes linked to anti-money laundering failures at its former Estonia branch and a US$2.00 billion settlement agreed in 2022. This conclusion removes a long-running regulatory overhang from one of Europe’s most high-profile financial crime cases, clarifying Danske Bank’s compliance position for regulators, clients, and investors. With the U.S. probation now concluded, we’ll...

Aktieselskabet Schouw (CPSE:SCHO) has kicked off a new share buy back programme, planning to repurchase up to DKK 120 million of stock through year end, which the company presents as a clear signal of management confidence. See our latest analysis for Aktieselskabet Schouw. The buyback news lands on top of a solid run, with the share price at DKK 626 and a roughly 8 percent 1 month share price return contributing to a stronger year to date trend and healthy multi year total shareholder...

It is hard to get excited after looking at Embla Medical hf's (CPH:EMBLA) recent performance, when its stock has...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

If you have been wondering whether Novo Nordisk is a bargain or a value trap at today’s price, you are not alone. This article is going to walk you through the key numbers that actually matter. The shares recently closed at 309.35, with a 3.4% gain over the last 7 days, a roughly flat -0.5% over 30 days, but a sharp slide of -51.6% year to date and -58.7% over the last year. This tells us the market’s view of its risk and growth potential has shifted dramatically, despite a still respectable...

Pandora (CPSE:PNDORA) is back in focus after the board accelerated its leadership transition, moving Berta de Pablos-Barbier into the CEO seat earlier than planned. This shift could subtly reshape the jewelry maker’s strategy. See our latest analysis for Pandora. The leadership shake up is landing against a tough backdrop, with a roughly 46 percent year to date share price return in negative territory and a 42 percent negative total shareholder return over 12 months. However, the three year...

Ringkjøbing Landbobank recently reported that, under its ongoing share buyback programme running until 30 January 2026, it has repurchased 612,277 shares for up to DKK 1,000 million, equivalent to 4.04% of its share capital. This progress update highlights a substantial capital allocation towards reducing the share count, which can meaningfully influence ownership concentration and per-share metrics. We’ll now explore how this sizeable DKK 1,000 million buyback commitment shapes Ringkjøbing...

Jyske Bank (CPSE:JYSK) has quietly delivered a strong run for shareholders, with the stock up about 7% over the past month and roughly 18% in the past 3 months. That outperformance raises a clear question: does the current price still make sense? See our latest analysis for Jyske Bank. Zooming out, that recent momentum sits on top of a powerful trend, with a year to date share price return above 60% and a five year total shareholder return near 300%. This suggests sentiment has steadily...